Credit Suisse AG grew its stake in GALAPAGOS NV/S (NASDAQ:GLPG) by 52.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,376 shares of the biotechnology company’s stock after buying an additional 65,094 shares during the period. Credit Suisse AG owned 0.37% of GALAPAGOS NV/S worth $21,404,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Trexquant Investment LP acquired a new stake in shares of GALAPAGOS NV/S during the third quarter valued at about $256,000. BlackRock Inc. increased its position in shares of GALAPAGOS NV/S by 18.4% during the third quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock valued at $41,083,000 after acquiring an additional 56,848 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of GALAPAGOS NV/S during the third quarter valued at about $5,183,000. American National Insurance Co. TX acquired a new stake in shares of GALAPAGOS NV/S during the third quarter valued at about $394,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of GALAPAGOS NV/S during the third quarter valued at about $399,000. 15.45% of the stock is owned by institutional investors and hedge funds.
Shares of GLPG stock opened at $100.72 on Monday. The company has a market capitalization of $5.16 billion, a P/E ratio of -38.15 and a beta of 1.91. GALAPAGOS NV/S has a fifty-two week low of $84.13 and a fifty-two week high of $122.28.
A number of equities research analysts have weighed in on GLPG shares. Stifel Nicolaus lifted their price target on shares of GALAPAGOS NV/S from $109.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, September 12th. BidaskClub cut shares of GALAPAGOS NV/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 17th. ValuEngine cut shares of GALAPAGOS NV/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 17th. Nomura lifted their price target on shares of GALAPAGOS NV/S from $124.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, October 30th. Finally, Zacks Investment Research upgraded shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Tuesday, October 30th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. GALAPAGOS NV/S presently has an average rating of “Buy” and a consensus target price of $121.44.
COPYRIGHT VIOLATION NOTICE: “Credit Suisse AG Has $21.40 Million Position in GALAPAGOS NV/S (GLPG)” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/03/credit-suisse-ag-has-21-40-million-position-in-galapagos-nv-s-glpg.html.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Story: Is a Roth IRA right for you?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.